Joseph Damasio - Biostage Chief Officer
| BSTGDelisted Stock | USD 4.20 0.09 2.10% |
Insider
Joseph Damasio is Chief Officer of Biostage
| Age | 49 |
| Phone | 774 233 7300 |
| Web | https://biostage.com |
Biostage Management Efficiency
The company has return on total asset (ROA) of (2.1066) % which means that it has lost $2.1066 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.9228) %, meaning that it created substantial loss on money invested by shareholders. Biostage's management efficiency ratios could be used to measure how well Biostage manages its routine affairs as well as how well it operates its assets and liabilities.Biostage currently holds 115 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Biostage has a current ratio of 2.21, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Biostage until it has trouble settling it off, either with new capital or with free cash flow. So, Biostage's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biostage sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biostage to invest in growth at high rates of return. When we think about Biostage's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Dr MBA | Cellectis SA | 46 | |
| MEng CFA | Antibe Therapeutics | N/A | |
| Chris Cargill | Sosei Group | 39 | |
| Philip Stern | Antibe Therapeutics | N/A | |
| Pascalyne Wilson | Cellectis SA | N/A | |
| Kazumi Sawaguchi | SanBio Company Limited | N/A | |
| Jay Carlson | Mosaic Immunoengineering | N/A | |
| MSc MSc | Cellectis SA | 54 | |
| Hironoshin Nomura | Sosei Group | N/A | |
| Kieran FCA | Sosei Group | N/A | |
| MBA MSc | Antibe Therapeutics | 65 | |
| Kyung NamWortman | Cellectis SA | 53 | |
| Cyril Empig | Mosaic Immunoengineering | N/A | |
| Kazuhiko Yoshizumi | Sosei Group | 69 | |
| Akihiro MBA | SanBio Company Limited | 56 | |
| Simon Smith | Covalon Technologies | N/A | |
| Candelle Chong | Sosei Group | N/A | |
| Ron Hebert | Covalon Technologies | N/A | |
| Bijan Nejadnik | SanBio Company Limited | 61 | |
| Naoki Tsukahara | SanBio Company Limited | N/A | |
| Jason Gorel | Covalon Technologies | N/A | |
Management Performance
| Return On Equity | -4.92 | |||
| Return On Asset | -2.11 |
Biostage Leadership Team
Elected by the shareholders, the Biostage's board of directors comprises two types of representatives: Biostage inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biostage. The board's role is to monitor Biostage's management team and ensure that shareholders' interests are well served. Biostage's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biostage's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yu Hong, President | ||
| Joseph Damasio, Chief Officer | ||
| David Green, CEO Chairman | ||
| Shunfu Hu, VP Operations | ||
| William Fodor, Chief Officer |
Biostage Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Biostage a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.92 | |||
| Return On Asset | -2.11 | |||
| Current Valuation | 78.64 M | |||
| Shares Outstanding | 11.64 M | |||
| Shares Owned By Insiders | 50.95 % | |||
| Number Of Shares Shorted | 121.66 K | |||
| Price To Earning | (0.16) X | |||
| Price To Book | 28.47 X | |||
| EBITDA | (8.36 M) | |||
| Net Income | (7.98 M) |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in Biostage OTC Stock
If you are still planning to invest in Biostage check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biostage's history and understand the potential risks before investing.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |